Jump to content

User:Disolution

From Wikipedia, the free encyclopedia

Trevor Lane Broadt (born July, 1968) is a molecular biologist and quality control manager for the National Cancer Institute's Biopharmaceutical Development Program located at Fort Detrick, Maryland.

Introduction

[edit]

Trevor was born and grew up in rural Lewisburg, Pennsylvania, the son of an entrepreneurial family. He attended the Pennsylvania State University graduating with an A.A. in Business and a B.A. in Anthropology. He later attended the University of Maryland Baltimore County (UMBC) where he earned a M.S. in Applied Molecular Biology and a graduate certificate in Biochemical Regulatory Engineering. Trevor lives in Braddock Heights, Maryland with his wife, the scientist and pathologist Heidi Agostini, and their two children.

Technical activities

[edit]

After completing his Master's degree in molecular biology, Trevor managed the $183M revenue Enzyme Manufacturing and Quality division of Life Technologies, Inc. (now Invitrogen Corp.). Following Invitrogen's aquisition of Life Technologies in 2000, he joined the Biopharmaceutical Development Program(BDP), a directorate of the National Cancer Institute at Fort Detrick, Maryland. He currently manages biopharmaceutical release and stability testing for phase I CGMP biopharmaceuticals manufactured by the BDP.

Organizations

[edit]

Publications and Patents

[edit]

Identifying the safety profile of a novel infectivity-enhanced conditionally replicative adenovirus, Ad5-delta24-RGD, in anticipation of a phase I trial for recurrent ovarian cancer.
American Journal of Obstetrics and Gynecology. 2007 Apr;196(4):389.

Preclinical manufacture of an anti-HER2 scFv-PEG-DSPE, liposome-inserting conjugate.
Biotechnology Progress. 2005 Jan-Feb;21(1):205-20.

Education

[edit]


Notes

[edit]
[edit]